AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process. "The value of AI in our industry is productivity improvement," Soriot said on CNBC's " Mad Money " on Friday. "In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter." The comments come as investors increasingly question whether the massive spending on artificial intelligence is producing …